Jazz Pharmaceuticals' fair value estimate has nudged up from $206.38 to $208.50 per share as analysts recalibrate their models around stronger long term growth prospects, particularly tied to the Ziihera oncology franchise. With the discount rate effectively steady at 7.34% and revenue growth expectations edging higher from 7.42% to 7.60%, the story now centers on how a reshaped HER2 positive GEA landscape could sustain a more robust top line over time. Stay tuned to see how you can track these evolving expectations and keep ahead of the shifting narrative around Jazz's stock.

Stay updated as the Fair Value for Jazz Pharmaceuticals shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Jazz Pharmaceuticals.

???? Bullish Takeaways

Analysts are broadly positive on Jazz, with multiple firms lifting targets into the high $100s and low $200s as Ziihera phase 3 HERIZON GEA data sharpen growth visibility and support a higher fair value range.

Morgan Stanley, RBC Capital, Jefferies and Truist all frame Ziihera as a potential new standard of care in 1L HER2 positive GEA, highlighting statistically significant and clinically meaningful progression free survival and overall survival benefits as key drivers of long term oncology growth.

Truist, raising its target to $220, characterizes Ziihera as a pipeline in a drug, arguing that HER2 positive indications beyond GEA could push peak sales above $2B and extend Jazz's growth runway well past current consensus modeling.

RBC Capital's move to a $194 target and Morgan Stanley's series of upward revisions, now as high as $205, underscore confidence that Jazz's strategic pivot to a more diversified oncology portfolio, including royalty economics from Lumryz and expanding Xywav penetration, can offset future erosion in legacy oxybate revenues.

BofA's lift to a $230 target, alongside a maintained Buy rating, reflects appreciation for solid execution and relatively stable fundamental trends, even as the firm does not anticipate major near term earnings surprises. This suggests that some upside from improved pricing, volume and pipeline momentum is already being embedded into valuation.

???? Bearish Takeaways

Even the more constructive analysts flag that limited disclosure around detailed HERIZON GEA endpoints, timing of the planned sBLA in 1H26 and competitive dynamics in HER2 positive cancers introduce execution and regulatory timing risk that could challenge Jazz's ability to fully realize the implied growth baked into rising targets.

Several firms note that after a string of target upgrades into the $190 to $230 band, some of Ziihera's potential and incremental oxybate related cash flows may already be reflected in the share price. This may constrain near term upside if subsequent data cuts or launch metrics fall short of current expectations.

JPMorgan's modest trim of its target to $199 ahead of Q3, even while keeping an Overweight rating, points to a more cautious strand of sentiment that focuses on near term modeling risks, possible volatility around quarterly results and the need for consistent execution across both sleep and oncology franchises to justify the higher valuation bar.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Jazz reported positive top line Phase 3 HERIZON GEA 01 results, with Ziihera plus chemotherapy, with or without PD 1 inhibitor Tevimbra, delivering highly statistically significant and clinically meaningful improvements in progression free survival and overall survival versus trastuzumab plus chemotherapy in first line HER2 positive GEA. Data submissions to major meetings and NCCN Guidelines are planned for 2026.

Two key Ziihera abstracts were accepted for presentation at the ASCO GI Cancers Symposium in January 2026 in San Francisco, and Jazz plans to host an investor webcast to review the data, signaling rising visibility and investor focus on the asset's pivotal dataset.

Modeyso, Jazz's recently FDA approved therapy for H3 K27M mutant diffuse midline glioma, received a category 2A single agent recommendation in NCCN Guidelines for recurrent or progressive diffuse high grade glioma with H3 K27M mutation, strengthening its positioning in neuro oncology treatment pathways.

The FDA approved Zepzelca in combination with atezolizumab, or atezolizumab and hyaluronidase, as the first combination maintenance regimen for extensive stage small cell lung cancer, following Phase 3 IMforte data that showed meaningful reductions in the risk of disease progression and death versus atezolizumab alone. Jazz also modestly raised full year 2025 revenue guidance and narrowed its expected net loss, highlighting improving earnings visibility as oncology contributions grow.

Fair value estimate has risen slightly from $206.38 to $208.50 per share, reflecting modestly higher expectations for long term earnings power.

Discount rate is effectively unchanged, edging down marginally from 7.34% to 7.34%, implying a stable risk profile and cost of capital assumption.

Revenue growth has increased slightly from 7.42% to 7.60%, indicating a modestly more optimistic view of Jazz's long term top line trajectory.

Net profit margin has risen slightly from 18.71% to 18.89%, incorporating incremental operating leverage and profitability improvements.

Future P/E has decreased marginally from 15.88 times to 15.82 times, suggesting a modestly lower multiple applied to a slightly higher earnings base.

Narratives are clear, investor friendly stories that connect what a company does to what its numbers could look like in the future. On Simply Wall St's Community page, you can see how a Narrative links Jazz Pharmaceuticals' strategy to forecasts for revenue, earnings and margins, and then to an implied fair value. As news and earnings arrive, Narratives update dynamically, helping you quickly compare Fair Value to today’s Price and decide whether to buy, hold or sell.

Head over to the Simply Wall St Community and follow the Narrative on Jazz Pharmaceuticals to stay on top of:

How Ziihera's HER2 positive GEA success and label expansion could support multi year oncology leadership and upside to consensus revenue forecasts.

Whether neuroscience and cannabinoid therapies, like Xywav and Epidiolex, can offset patent cliffs, competitive threats and regulatory pricing pressure.

How leverage, acquisitions and R&D spending affect long term profit margins, the required future P/E of about 15.8x and fair value versus the current share price.

Read the full Jazz Pharmaceuticals Narrative on Simply Wall St and see the story behind the latest fair value estimate.

Curious how numbers become stories that shape markets? Explore Community Narratives

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include JAZZ.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com